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Background/aim: Aspartame (APM, L-aspartyl-L-phenylalanine methylester) is a low-calorie, nonsaccharide artificial sweetener widely
used in foods and beverages. When metabolized by the body, APM is broken down into aspartic acid, phenylalanine amino acids, and a third
substance, methanol. Since the amino acid phenylalanine serves as a neurotransmitter building block affecting the brain, and methanol is
converted into toxic formaldehyde, APM has deleterious effects on the body and brain. Thus, its safety and, toxicity have been the subjects
of concern ever since it was first discovered. Although many studies have been performed on it, due to the presence of conflicting data in the
literature, there are still numerous question marks concerning APM. Therefore, the safety of aspartame was tested using in vitro methods.
Materials and methods: We aimed to evaluate the in vitro cytotoxic effects by using 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) and lactate dehydrogenase release tests, genotoxic damage potential by using chromosome aberration (CA) assay, and
antioxidant/oxidant activity by using total antioxidant capacity (TAC) and total oxidative stress (TOS) analysis in primary human whole
blood cell cultures.
Results: The results of the MTT test showed that APM led to significant decreases in cell viability in a clear concentration-dependent
manner. Moreover, an increase in CA frequency was found in the cells treated with APM. However, APM treatments did not cause any
significant changes in TAC and TOS levels in whole blood cultures.
Conclusion: Overall, the obtained results showed that APM had genotoxicity potential and a concentration-dependent cytotoxic activity
in human blood cells.
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1. Introduction
High intensity-sweeteners (HIS) are natural, semisynthetic, or synthetic chemical substances used as an
alternative to sugar in food products, beverages, and
some oral medications. Aspartame (APM), a member of
the semi-synthetic sweetener group, was first discovered
incidentally in 1965 by the chemist James M. Schlatter
during research into anti-ulcer drugs [1,2]. APM was
approved as an artificial sweetener by the Food and Drug
Administration (FDA) in 1981 [3], and is used in more
than 6000 products, in non-alcoholic beverages, chewing
gum, sugar, yoghurt, and some pharmacological products
such as sugar-free cough drops [4]. Following its approval

by the FDA, APM has become a sweetener increasingly
used in both diabetics and obese patients on weight
loss programs, and also in healthy individuals as a food
additive.
At the reports of American Dietetic Association, World
Health Organization (WHO) and Food and Agriculture of
the United Nations have determined an acceptable daily
intake (ADI) as a conservative estimate that can be used
as a safety marker for artificial sweeteners. In 2005, the
FDA set that value as 50 mg/kg for APM, while in 2006
European Food Safety Authority (EFSA, 2006) set it as
40 mg/kg [5]. Following oral intake, APM is absorbed by
the intestinal lumen and hydrolyzed into phenylalanine
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(50%), aspartic acid, an excitatory amino acid (40%), and
methanol (10%) [6]. It acquires its sweetness from T1R2
and T1R3, from the T1R class receptor family, a G proteincoupled receptor family [7].
Chronic exposure to APM, one of the six generally
recognized as safe (GRAS) non-nutritive sweeteners (NNS)
recognized by the FDA in the USA (saccharine, aspartame,
sucralose, neotame, acesulfame-K, and stevia), has been
reported to cause neurological disorders such as headache,
eye problems including blurred vision, insomnia, torpor,
memory loss, nausea, speech impairment, personality
changes, loss of energy, hyperactivity, and hearing
problems [8,9]. The data in the literature concerning the
molecule APM, regarded as safe and approved for use by
the FDA, are inconsistent, though some show side-effects
associated with APM use. Doubts concerning the use of
the APM molecule persist to this day due to reports that
it can cause neurological damage and induce apoptosis
by adversely affecting the oxygen balance in brain [10],
degenerative damage in nerve cells [11], liver and kidney
damages via increased oxidative stress [6,9,12] and also
cancer development due to its carcinogenic effects on the
entire body [4,13]. To the best of our knowledge no study
has been conducted to investigate the cytotoxic, genotoxic,
and oxidative potentials of APM on human blood cells.
Therefore, in the present study, in vitro biological activities
of APM were determined via measuring cytotoxicity,
genotoxicity, and oxidative damage levels in cultured
human blood cells for the first time.
2. Methods
2.1. MTT assay
Whole heparinized human blood samples (10 mL)
was collected from five healthy, male, non-smoking
donors between the ages of 22 and 25 years, with no
history of exposure to any genotoxic agent. Peripheral
blood mononuclear cells (PBMC) were collected by
centrifugation on Ficoll-Hypaque gradient (Cambrex; 800
g, 20 min, without brake) and placed in a 96-well plate
containing the growth medium. The cells were treated with
different concentrations (3.125, 6.25, 12.5, 25, 50, and 100
mg/L) of APM for 48 h. At the end of incubation, 5 mg/mL
MTT solution was added to each well and incubated for 4
h. To solubilize formazan crystals, dimethyl sulfoxide was
added to each well and the absorbance was measured at
570 nm using a spectrophotometer (Synergy-HT; BioTek
Winooski, VT, USA). Triton X-100 treated cells were used
as positive control and the cells without any treatment
were used as a negative control.
2.2. Lactate dehydrogenase (LDH) release assay
PBMC were placed in a 96-well plate containing the
growth medium and exposed to different concentrations
(3.125, 6.25, 12.5, 25, 50, and 100 mg/L) of APM for 48 h.

After the incubation period, LDH assay was carried out
using a commercial kit (CytoSelectTM LDH Cytotoxicity
Assay kit) according to the provider’s instructions. Briefly,
90 µL of the supernatant from each well was mixed with
10 μL of LDH reagent and incubated at 37 °C for 30 min.
The optical density was determined at 450 nm using a
spectrophotometer (Synergy-HT; BioTek Winooski, VT,
USA). Triton X-100-treated cells were used as positive
control and the cells without any treatment were used as
a negative control.
2.3. Total antioxidant capacity (TAC) and total oxidant
status (TOS) assays
PBMC was seeded in a 48-well plate and treated with
various concentrations (3.125, 6.25, 12.5, 25, 50, and
100 mg/L) of APM for 48 h at 37 °C with 5% CO2. Then,
plasma samples were collected to perform TAC (Rel
Assay Diagnostics®,Turkey) and TOS assay Rel Assay
Diagnostics®, according to the provider’s guide.
2.4. CA assay
Human blood cells were treated with APM at IC50
concentration and cultured for 72 h in an incubator.
Colchicine (0.02 μg/mL) was added to the samples 2 h
before the harvest of cells. At the end of 72 h, the cells
were collected by centrifugation after hypotonic treatment
(0.075 M KCl) and fixation with methanol/acetic acid. The
fixed-cell suspension was dropped on glass slides. Then,
air-dried slides were stained with Giemsa in phosphate
buffer (pH 6.8). Fifty well-spread metaphases were
counted and scored for chromosome aberration according
to the Environmental Health Criteria 46 for environmental
monitoring of human populations (IPCS, 1985).
2.5. Ethics
The study was approved by the local Ethics Committee
(2019/03-29) and was in accordance with the Declaration
of Helsinki and the International Conference on
Harmonization for Good Clinical Practice. Written
informed consent was obtained from all patients.
2.6. Statistical analysis
Statistical analysis was performed using SPSS software
(version 18.0, SPSS, Chicago, IL, USA). Duncan’s test was
used for the statistical analysis of experimental values in
the MTT, LDH, CA, TAC, and TOS analysis. Statistical
decisions were made with a significance level of 0.05.
3. Results
3.1. Cytotoxicity assays
After treatments with different concentrations of APM for
48 h, cytotoxicity was examined using colorimetric and
enzymatic methods including MTT and LDH assays. The
results of MTT assay are presented in Figure 1. According
to the obtained results, APM treatment showed a low
impact on cell viability but in a concentration-dependent
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manner. The LDH activities of different concentrations
of APM on blood cells are represented in Figure 2. The
obtained results are similar to MTT assay results. The
IC50 value of APM on lymphocyte cells was calculated
according using MTT assay results as 287.342 mg/L.
3.2. Antioxidative/oxidative assays
To investigate the potential antioxidative/oxidative effects
of APM on human blood cells, TAC and TOS assays were
used to determine total antioxidant and oxidant levels.
According to the TAC assay results, the highest TAC level
was observed in the cells treated with 6.25 mg/L APM.
On the other side, concentrations lower than 50 mg/L of
APM did not cause significant alteration in TOS level.
When compared to the control group, 50 and 100 mg/L of
APM increased the TOS levels. The results of TOS levels
are presented in Figure 3 and the results of TAC levels in
Figure 4.

3.3. Genotoxicity assays
Figure 5 shows the results of CA assay in lymphocytes.
Based on the results, CA frequency is 0.24, 0.68, and
0.43 in negative control group, positive control group,
and APM-treated group, respectively. Mitomycin C
used as a positive control caused significant increases in
CA frequencies. Moreover, APM at IC50 concentration
induced a considerable increase in formations of CA when
compared to control group.
4. Discussion
APM is rapidly and completely metabolized into its amino
acid components (aspartic acid and phenylalanine) and
methanol following absorption. Studies have shown that
rapidly metabolized APM is dispersed throughout the
body, particularly in organs with rapid protein manufacture
and breakdown [14]. The APM molecule has always been

Figure 1. Viability of human blood cells after 48 h of exposure to 0–100 mg/L APM. Control (-):
negative control; Control (+): positive control.

Figure 2. LDH activities in cultured human blood cells treated with different
concentrations (0–100 mg/L) of APM for 48 h. The abbreviations are the same as
those in Figure 1.
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Figure 3. TOS levels in cultured human peripheral blood cells
exposed to APM for 48 h. The abbreviations are the same as those
in Figure 1.

the subject of research into its safety and toxicity due to
the presence in neurotransmitters acting on the brain of
phenylalanine resulting from APM metabolism being
capable of leading to neurobiochemical and behavioral
changes [15], and to the conversion of methanol to toxic
formic acid.
Methanol and its short-lived oxidized product
formaldehyde are compounds naturally present in normal
healthy individuals. Sources of human physiological
methanol include fruit and vegetables, the fermentation
of intestinal bacteria, and metabolic processes involving
S-adenosyl methionine. Blood methanol concentrations
in healthy humans are estimated to range between 0.20 ±

Figure 4. TAC levels in cultured human peripheral blood cells
exposed to APM for 48 h. The abbreviations are the same as those
in Figure 1.

0.035 and 5.37 ± 0.08 mg/L, and these values are reported
to be 400–1000 times lower than the toxic concentration
[16]. The World Health Organization (WHO) reports that
the average adult receives 1.5–14 mg per day (mean 7.75
mg per day) formaldehyde via foodstuffs [17]. The halflife of formaldehyde in humans is 1–1.5 min, while stable
blood and intracellular concentrations are estimated 2.6
mg/L (87 μM) and 12 mg/L (400 μM), respectively. Using
real usage data and based on EFSA Scientific Panel on Food
Additives and Nutrient Sources Added to Food analysis,
APM use is estimated to contribute 0.5–9.7% of daily total

Figure 5. Representative images of chromosomal aberrations observed in cultured
human peripheral blood cells. (A: Control group, B: Treatment with APM in IC50 dose).
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endogenous and exogenous methanol exposure. At ADI
dosages, an approximately 4 mg/kg formaldehyde burden
arises with APM use, and this contributes only 0.3–0.4%
of exposure to formaldehyde of endogenous and dietary
origins [18]. For these reasons, APM is thought to be safe
by world health authorities.
The safety of APM has been investigated by in vitro
and in vivo studies. In the present study, we mainly
explored in vitro cytotoxic, genotoxic damage potential
and antioxidant/oxidant activity of APM in primary
human whole blood cell cultures. Our finding showed that
APM led to decreasing in cell viability in a concentration
dependent manner. APM at concentrations greater than
25 mg/L significantly reduced cell viability. There have
been previous studies of APM and its cytotoxic effects, but
the results are inconsistent. Similar to our results, Horio et
al. reported that cell vitality decreased in a concentration
-dependent manner following exposure of PC12 cells to
0–8 μg/mL APM for 72 h, and that a severe decrease in cell
vitality occurred at higher concentrations than 1 μg/mL
APM [19]. In addition, Sonnewald et al. [20] detected that
APM increased the release of LDH from cerebral granular
neurons and 45Ca influx into the cell, and that it led to
cell damage, in a concentration-dependent manner. The
studies have shown that the cytotoxic effect induced by
APM exposure may be associated with the oxidative stress
[21]. Because formic acid, the final product of methanol
metabolism, causes hypoxia at the cellular level due to its
inhibition of cytochrome oxidase, the terminal member
of the mitochondrial electron transport chain, and results
in oxidative stress. Therefore, methanol is an aspartame
metabolite that is a toxicant and causes systematic toxicity
[22].
Due to the concerns that oxidative homeostasis can
be adversely affected by methanol metabolism occurring
with APM use, studies have also investigated oxidative
homeostasis in various organs in association with APM
use. In the current study TAC and TOS levels did not
significantly change in the cells treated with APM.
However, rat studies have reported an increase in oxidative
stress characterized by increased lipid peroxidation levels,
and a decrease in levels of such antioxidant molecules as
reduced glutathione and protein thiol, in erythrocytes
[23,24], heart [25], brain [26,27], liver and kidney [27]
tissues with APM use.
In our study, we determined an increase in CA
frequency in human lymphocyte culture exposed to an
IC50 concentration. These are in agreement with studies in
which the genotoxic effect of APM has been investigated
using the CA test. It has been reported that APM induces
CA in mouse bone marrow cells at doses of 35 and 350
mg/kg bw [28] and in human lymphocyte culture at
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concentrations of 500, 1000, and 2000 μg/mL [29]. At
the same time, publications have also reported that it
leads to DNA damage in mouse bone marrow cells at 35
mg/kg at comet-tail DNA analysis due to DNA filament
breaks [30], and that in its current form it is genotoxic.
Conversely, previous studies have also reported that it
did not increase sister chromatid exchange (SCE) [28,29]
and was not mutagenic at Ames test analysis involving
Salmonella typhimurium strains [29,30]. Otherwise,
APM was described as a moderately genotoxic agent
[31]. However, it was reported that no evidence of gene
mutation induction in a series of bacterial mutation
tests, and that although there was evidence of in vitro
chromosome damage induction, this occurred secondary
to cytotoxicity and did not involve primary DNA damage
[32].
In addition to studies reporting a genotoxic effect
of APM with in vitro tests, there has also been research
into its carcinogenic effect under in conditions. Soffriti
et al. [13] reported increased renal pelvis transitional
cell carcinoma and peripheral nerve schwannoma in
Sprague–Dawley rats following the administration of
the APM in diet. In another study investigating the
effect on risk of fetal malignancy following exposure to
APM in fetal life, Soffriti et al. [33] reported an increased
incidence of lymphoma/leukemia in male and female
rats and of breast cancer in female rats. In addition,
Combos et al. [34] reported a significant increase Haras and c-myc oncogens and p53 tumor suppressor gene
expressions in lenforeticular, bone marrow, and kidney
tissues in rats exposed to dosages of 40, 200, and 2500
mg/kg. Among those studies reporting that the APM
molecule has no carcinogenic effect, some have stated
that it does not increase the risk of hematopoietic or
brain cancer in humans [35], that it causes no increase in
the development, growth, or fatality of pancreatic acinar
carcinoma in mice [36], and that there is no association
with the risk of neoplasm in humans [37].
In conclusion, the result of this study demonstrates
that APM has a moderate cytotoxic activity and causes
no significant effect on antioxidative/oxidative activity on
human blood cells. Moreover, APM is potential genotoxic
agent in human blood cells. Thus, usage of APM should
be monitored and limited due to its adverse effects. Our
study will promote further research related to the safety
of APM.
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